Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Marketing Authorization for the Spleen Tyrosine Kinase Inhibitor TAVALISSE in South Korea
Details : Tavalisse (fostamatinib disodium hexahydrate) is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Kissei Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Tempus And JW Pharmaceutical Partner for Data-Based Early R&D
Details : The collaboration aims to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Oncocross
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development
Details : The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 27, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Oncocross
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Kissei Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sub-licensing Agreement for Fostamatinib with JW Pharmaceutical Corporation
Details : JW Pharma will be responsible for the development and commercialization rights in Korea for Tavalisse (fostamatinib), a spleen tyrosine kinase inhibitor for treating immune thrombocytopenia.
Product Name : Tavalisse
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Fostamatinib Disodium Hexahydrate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Kissei Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : CWP291
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy
Details : CWP291 is a Wnt/beta-catenin inhibitor that is under development as a first-in-class treatment for acute myeloid leukemia, multiple myeloma and stomach cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : CWP291
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2012
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2012
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable